Mutual Advisors LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 15,334 shares of the medical research company’s stock after selling 1,882 shares during the quarter. Mutual Advisors LLC’s holdings in Amgen were worth $4,132,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of the stock. Talbot Financial LLC grew its stake in shares of Amgen by 5.6% during the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company’s stock valued at $11,153,000 after buying an additional 2,274 shares during the last quarter. Swiss National Bank grew its position in Amgen by 0.3% in the 3rd quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company’s stock valued at $513,033,000 after acquiring an additional 5,500 shares during the last quarter. Asset Advisors Investment Management LLC increased its stake in Amgen by 9.0% in the third quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company’s stock worth $11,578,000 after purchasing an additional 2,954 shares during the period. Principal Financial Group Inc. lifted its position in shares of Amgen by 6.0% during the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company’s stock worth $204,659,000 after purchasing an additional 35,785 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Amgen by 3.2% during the third quarter. First Horizon Advisors Inc. now owns 60,769 shares of the medical research company’s stock valued at $19,581,000 after purchasing an additional 1,872 shares during the period. 76.50% of the stock is currently owned by institutional investors.
Amgen Price Performance
Shares of AMGN stock opened at $277.88 on Friday. The firm has a market capitalization of $149.37 billion, a price-to-earnings ratio of 35.58, a PEG ratio of 2.79 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The stock’s 50-day simple moving average is $271.91 and its 200-day simple moving average is $306.43. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.
Amgen Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.43%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on AMGN shares. Leerink Partners reduced their price target on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Truist Financial decreased their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. TD Cowen boosted their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Sanford C. Bernstein assumed coverage on Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective on the stock. Finally, Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $314.91.
View Our Latest Analysis on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What Are Treasury Bonds?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Stock Market Sectors: What Are They and How Many Are There?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.